HFD administration for 12 weeks led to a considerable decrease in serum PON1 activity (2.31‐fold) in the NAFLD group compared with that in the control group (p = 0.011; Figure 3B). This evidence concerns the gene PON1 and metabolic dysfunction-associated steatotic liver disease.